ArticleInflammopharmacology2026
Arbutin mediated neuroprotection in zebrafish model of traumatic brain injury via modulating Nrf2/NF-κB pathway.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic Brain Injury (TBI) is a major cause of mortality and disability worldwide and is associated with oxidative stress, neuroinflammation, and neurotransmitter imbalance. Arbutin, a naturally occurring glycoside with known antioxidant and anti-inflammatory properties, has the potential to modulate neurochemical alterations following brain injury. The present study was designed to evaluate the neuroprotective effects of arbutin in a zebrafish model of TBI induced by a novel non-invasive mechanical impact method termed "force-induced TBI." Adult zebrafish were randomly divided into seven groups (n = 14 per group): normal control, TBI control, arbutin per se, arbutin-treated groups (25, 50, and 100 mg/kg, i.p.), and a co-treatment group receiving arbutin (100 mg/kg) co-administrated with chrysin (25 mg/kg), a known modulator of the Nrf2/NF-κB signaling pathway. Behavioural assessments, including the open field test, novel tank diving test (NTDT), T-maze, and novel object recognition test (NORT), were conducted on days 1, 4, and 7 to evaluate locomotion activity, anxiety-like behaviour, spatial memory, and recognition ability, respectively. Following behavioural evaluation, brain tissues were analysed for oxidative stress markers (MDA, nitrite, GSH, and SOD), neurotransmitter levels (GABA and glutamate), pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), and histopathological alterations. Immunohistochemical analysis of Nrf2 and NF-κB was also performed. The results demonstrated that arbutin significantly improved behavioural performance, restored oxidative balance, normalized neurotransmitter levels, and attenuated neuroinflammatory responses. Furthermore, arbutin treatment was associated with increased Nrf2 immunoreactivity and reduced NF-κB immunoreactivity in a dose-dependent manner. The co-treatment with chrysin also exhibited protective effects, supporting its potential modulatory role in oxidative stress and these effects are associated with modulation of oxidative stress, neuroinflammation, neurotransmitter imbalance, and Nrf2/NF-κB immunoreactivity. These findings suggest that arbutin possesses neuroprotective potential against secondary brain injury and is associated with modulation of oxidative stress, inflammatory responses, and Nrf2/NF-κB immunoreactivity.
Indexed as
Identifiers
42525318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.